ADVERSE EFFECTS OF RADIOACTIVE IODINE THERAPY IN THYROID CANCER SURVIVORS: IMPLICATIONS FOR QUALITY OF LIFE

Autores

  • Rafael de Oliveira Tabian
  • Rodolfo de Oliveira Medeiros
  • Vitor Piacenti Padovan
  • Cristiano Machado Galhardi
  • Kayke Alexandre Sepero Gonçalves
  • Lucas Ramos Domingues
  • Vinicius Willian Calderon da Silva
  • Lyssa Miyagi Oku
  • João Reis Kingo
  • Hugo Henrique da Silva Nespolo
  • Gustavo Silveira Pires
  • Hugo Calesso dos Reis
  • Mario Raymundo Alves
  • Manuela Nunes Amaral
  • Felipe de Novais

DOI:

https://doi.org/10.36557/2009-3578.2025v11n2p1492-1506

Palavras-chave:

Radioiodine Therapy; Thyroid Cancer; Cancer Survivorship.

Resumo

Objective: This study aimed to analyze, through an Integrative Literature Review, the adverse effects of radioactive iodine (I-131) therapy in thyroid cancer survivors, with emphasis on psychosocial repercussions and quality of life after treatment. Method: The research was conducted in the PubMed, SciELO, Web of Science, LILACS, and Scopus databases, using controlled descriptors and free terms related to the topic. Articles published between 2015 and 2025 were included, in Portuguese, English, or Spanish, addressing physical and psychosocial effects of I-131 in thyroid cancer patients after medical discharge. The study selection followed PRISMA guidelines, and the data were systematized through a synthesis table, with methodological classification based on the Joanna Briggs Institute criteria. Results: Eleven articles were selected to compose the review corpus. The studies revealed a range of side effects associated with radioiodine therapy, such as salivary and lacrimal gland dysfunction, altered taste, chronic fatigue, and risk of secondary neoplasms. In the psychosocial domain, feelings of anxiety, insecurity, changes in body image, social isolation, and a perception of prolonged medicalization of life were highlighted. These findings indicate that surviving cancer does not necessarily equate to full well-being, requiring broader attention from healthcare services. Conclusion: Although effective from an oncological perspective, radioiodine therapy imposes long-lasting repercussions on patients’ lives. Recognizing the functional and subjective impacts as part of the therapeutic process is essential to ensuring quality of life, autonomy, and dignity throughout the thyroid cancer survivorship journey.

Downloads

Não há dados estatísticos.

Referências

BANIHASHEM, S. et al. Psychological status and quality of life associated with radioactive iodine treatment of patients with differentiated thyroid cancer: results of Hospital Anxiety and Depression Scale and Short-Form (36) Health Survey. Indian Journal of Nuclear Medicine, v. 35, n. 3, p. 216–221, Jul./Sep. 2020. Available at: https://pubmed.ncbi.nlm.nih.gov/33082677/. Accessed on: July 15, 2025.

BARBUS, E. Psychological impact of 131I radioprotection measures on thyroid cancer patients. Clujul Medical, v. 91, n. 4, p. 441–447, Oct. 30, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296732/. Accessed on: July 16, 2025.

CABANILLAS, M. E.; HABRA, M. A. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treatment Reviews, v. 42, p. 47–55, 2016. Available at: https://doi.org/10.1016/j.ctrv.2015.11.003. Accessed on: July 16, 2025.

CARVALHO, A. Y. et al. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment. Archives of Endocrinology and Metabolism, v. 68, 2024. Available at: https://doi.org/10.20945/2359-4292-2022-0506. Accessed on: July 15, 2025.

CHANGCHIEN, T. C. et al. Mental health and quality of life of patients with differentiated thyroid cancer pre and post radioactive iodine treatment: a prospective study. Journal of Clinical Medicine, v. 13, n. 18, art. 5472, 2024. Available at: https://www.mdpi.com/2077-0383/13/18/5472. Accessed on: July 16, 2025.

DIONISI-VICI, M. et al. Distress, anxiety, depression and unmet needs in thyroid cancer survivors: a longitudinal study. Endocrine, v. 74, n. 3, p. 603–610, Jun. 18, 2021. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571224/. Accessed on: July 16, 2025.

GANONG, L. H. Integrative reviews of nursing research. Research Nursing Health, v. 10, n. 1, p. 01–10, 1987. Available at: https://pubmed.ncbi.nlm.nih.gov/3644366/. Accessed on: July 15, 2025.

HIROMASA, T. et al. Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights. European Thyroid Journal, v. 14, n. 2, 2025. Available at: https://doi.org/10.1530/ETJ-24-0319. Accessed on: July 15, 2025.

KAEWPUT, C.; PUSUWAN, P. Outcomes following I-131 treatment with cumulative dose exceeding or equal to 600 mCi in differentiated thyroid carcinoma patients. World Journal of Nuclear Medicine, v. 20, n. 1, p. 54–60, Aug. 22, 2020. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034781/. Accessed on: July 16, 2025.

LEMES, M. A. et al. Evaluation strategies in active learning in higher education in health: integrative review. Revista Brasileira de Enfermagem, v. 47, n. 2, 2021. Available at: https://www.scielo.br/j/reben/a/KG8VgQhpKf9ySfCwjkyNY6w/?format=pdf&lang=en. Accessed on: July 15, 2025.

LI, X. et al. The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial. Frontiers in Endocrinology, v. 15, 2024. Available at: https://doi.org/10.3389/fendo.2024.1310223. Accessed on: July 15, 2025.

LIU, Y. et al. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy. Drug Resistance Updates, v. 68, 2023. Available at: https://doi.org/10.1016/j.drup.2023.100939. Accessed on: July 15, 2025.

LOCKWOOD, C. et al. Systematic reviews of qualitative evidence. In: AROMATARIS, E.; MUNN, Z. (Eds.). JBI Manual for Evidence Synthesis. JBI, 2020. Available at: https://jbi-global-wiki.refined.site/space/MANUAL/355860482. Accessed on: July 16, 2025.

MOHER, D. et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med, v. 6, n. 7, p. 1000097, 2009. Available at: https://pubmed.ncbi.nlm.nih.gov/19621072/. Accessed on: July 16, 2025.

PACE-ASCIAK, P. et al. Review: improving quality of life in patients with differentiated thyroid cancer. Frontiers in Oncology, v. 13, Jan. 26, 2023. Available at: https://doi.org/10.3389/fonc.2023.1032581. Accessed on: July 16, 2025.

STERN, C.; JORDAN, Z.; McARTHUR, A. Developing the review question and inclusion criteria. The American Journal of Nursing, v. 14, n. 4, p. 53–56, 2014. Available at: https://pubmed.ncbi.nlm.nih.gov/24681476/. Accessed on: July 16, 2025.

ZHAO, S. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer. Frontiers in Endocrinology, v. 14, 2023. Available at: https://doi.org/10.3389/fendo.2023.1320044. Accessed on: July 16, 2025.

YANG, Y. Guiding the postoperative radioactive iodine-131 therapy for patients with papillary thyroid carcinoma according to the prognostic risk groups: a SEER-based study. Journal of Cancer Research and Clinical Oncology, v. 149, n. 19, p. 17147–17157, Oct. 2, 2023. Available at: https://pubmed.ncbi.nlm.nih.gov/33082677/. Accessed on: July 16, 2025.

WANG, Z. The current state and influencing factors of negative social expectations among thyroid cancer patients: a single-center cross-sectional analysis. Frontiers in Psychology, v. 16, May 12, 2025. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12104241/. Accessed on: July 16, 2025.

Downloads

Publicado

2025-08-19

Como Citar

Tabian, R. de O., Medeiros, R. de O., Padovan, V. P., Galhardi, C. M., Gonçalves, K. A. S., Domingues, L. R., … Novais, F. de. (2025). ADVERSE EFFECTS OF RADIOACTIVE IODINE THERAPY IN THYROID CANCER SURVIVORS: IMPLICATIONS FOR QUALITY OF LIFE. INTERFERENCE: A JOURNAL OF AUDIO CULTURE, 11(2), 1492–1506. https://doi.org/10.36557/2009-3578.2025v11n2p1492-1506

Edição

v. 11 n. 2 (2025): IJAC - QUALIS A2

Seção

Revisão de Literatura

Licença

Copyright (c) 2025 Rafael de Oliveira Tabian, Rodolfo de Oliveira Medeiros, Vitor Piacenti Padovan, Cristiano Machado Galhardi, Kayke Alexandre Sepero Gonçalves, Lucas Ramos Domingues, Vinicius Willian Calderon da Silva, Lyssa Miyagi Oku, João Reis Kingo, Hugo Henrique da Silva Nespolo, Gustavo Silveira Pires, Hugo Calesso dos Reis, Mario Raymundo Alves, Manuela Nunes Amaral, Felipe de Novais

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Você tem o direito de:

  1. Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
  2. Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.

De acordo com os termos seguintes:

  1. Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
  2. Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.